Sensus Healthcare, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017; comparatives are for FY2016. Although the request refers to 2017 Q4, the supplied filing reports annual results and does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Sensus designs, manufactures and markets superficial radiation therapy systems, principally the SRT-100 product line, used to treat non-melanoma skin cancers and other skin conditions. It reported one operating segment. At year-end, it had an installed base of 334 units in 17 countries and a 21-person U.S. direct sales force. Revenue is primarily from device sales and related products and services.
Financial performance and liquidity
| Metric | FY2017 / Dec. 31, 2017 | FY2016 / Dec. 31, 2016 |
|---|---|---|
| Revenue | $20.59 million | $14.81 million |
| Gross profit / gross margin | $13.80 million / 67.0% | $9.85 million / 66.5% |
| Operating expenses | $17.52 million | $10.21 million |
| Operating loss | $(3.72) million | $(0.36) million |
| Net loss | $(3.71) million; $(0.28) per diluted share | $(0.35) million; $(0.03) per diluted share |
| Cash used in operating activities | $(3.06) million | $(0.85) million |
| Cash and cash equivalents | $10.09 million | $5.04 million |
| Investment in debt securities | $1.10 million | $7.57 million |
| Revolving credit borrowings | $2.21 million | None |
| Total assets / stockholders’ equity | $18.84 million / $11.68 million | $18.95 million / $15.27 million |
Revenue increased 39.0%, attributed to higher system volumes and a greater share of higher-priced SRT-100 Vision sales. Gross margin improved slightly, primarily with the Vision mix. Selling and marketing expense rose 69.0% to $8.31 million, and research and development expense rose 201.0% to $5.49 million; management attributed the R&D increase to new projects. The resulting operating and net losses widened substantially.
Year-end current assets were $17.89 million and current liabilities were $4.87 million. Cash, cash equivalents and investments totaled approximately $11.19 million; the company also had $2.21 million drawn on its revolving facility. Operating cash use increased year over year. Financing cash flow included $2.21 million of credit-facility borrowings; investing cash flow was positive primarily because debt securities matured. Management said available resources and borrowing capacity were sufficient for future operating and funding requirements, while noting that cash needs may change and additional funding may be considered.
Material changes and significant items
- Revenue rose $5.78 million year over year, while net loss increased from $0.35 million to $3.71 million.
- R&D spending increased by $3.67 million, mostly for development of an intra-operative radiation therapy device for breast and other cancers. The company filed a 510(k) application with the FDA in December 2017.
- The revolving credit facility was amended in October 2017, extending maturity to October 31, 2019, with a commitment of up to $5 million subject to borrowing-base terms and a $2.5 million non-formula sublimit. Interest rates at year-end were 5.25% on formula borrowings and 6.00% on non-formula borrowings. The facility is secured by company assets and contains restrictive covenants.
- The company was out of compliance with a financial covenant in April and May 2017; the defaults were waived and the covenants amended. It reported compliance as of December 31, 2017.
- The 2017 tax reform law reduced the federal corporate tax rate to 21% beginning in 2018. A $562,000 incremental tax expense from remeasuring deferred tax balances was offset by a valuation allowance; the reported tax provision was zero. The company maintained a full valuation allowance against its $1.12 million net deferred tax asset.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. The independent auditor issued an unqualified opinion on the financial statements but did not attest to internal-control effectiveness.
Outlook, commentary and risks
The filing provides no numerical revenue, earnings or cash-flow guidance. Management expected substantially all 2018 revenue to continue coming from the SRT-100 product line. It described potential growth in additional clinical markets and continued product development, but these opportunities depend on market adoption and regulatory outcomes. The company had received FDA 510(k) clearances for the SRT-100 and SRT-100 Vision; clearance of the IORT device was not assured.
- Profitability and cash: The company reported cumulative net losses of approximately $11.5 million through 2017, and operating cash use accelerated. Management’s ability to reach and sustain profitability is uncertain.
- Revenue concentration: One U.S. customer accounted for approximately 59% of 2017 revenue and 87% of year-end accounts receivable, compared with 20% and 39%, respectively, in 2016. Approximately 97% of 2017 revenue came from the U.S.; a customer in China accounted for approximately 2%.
- Product and market dependence: Substantially all revenue was generated by the SRT-100 line. Adoption depends on physician and patient acceptance, competition, pricing and third-party reimbursement.
- Manufacturing and supply: Production relies on a third-party manufacturer, and the company has a single preferred supplier for x-ray tubes. Management believed alternative tube supplies were available, but disruption could affect production.
- Regulatory, compliance and product risks: Medical-device clearances, quality requirements, restrictions on off-label promotion, healthcare fraud and abuse laws, privacy rules, product liability and potential recalls may create costs or interrupt sales.
- Credit and contractual restrictions: The secured credit facility includes a monthly adjusted quick-ratio covenant and restrictions on additional debt, asset transfers, investments and dividends. The company also disclosed approximately $956,000 in minimum office lease payments through 2022.
- Other exposures: Competition, intellectual-property challenges, cybersecurity, international trade and regulatory changes, and the company’s limited trading activity and concentrated ownership may affect results or share value. Ordinary-course legal proceedings were disclosed, without a clear quantified loss contingency in the filing text.
Important facts for investors to verify
- Customer concentration: the identity, ongoing purchasing commitments and credit quality of the customer responsible for 59% of FY2017 revenue and 87% of year-end receivables.
- Collections and working capital: receivable aging, subsequent receipts and the impact of increased accounts receivable on operating cash flow.
- Commercial momentum and margins: system sales volume, SRT-100 Vision mix, selling prices, gross-margin sustainability and sales-force productivity.
- IORT development: FDA review status and expected development, regulatory and commercialization costs; no approval or launch timing is guaranteed by this filing.
- Liquidity and lender terms: remaining facility availability under the borrowing base, covenant headroom, compliance after year-end and funding needs given ongoing losses and cash use.
- Revenue and reimbursement exposure: reliance on the SRT-100 line, reimbursement coverage and the extent of international demand beyond the U.S. and China.